Cellestia Biotech presents clinical results from the Phase 1 study of its novel gene transcription factor inhibitor CB-103 in advanced solid tumors at the 2021 ASCO Annual Meeting.
The clinical outcome and biomarker data generated in the Phase 1 confirm that CB-103 achieves highly potent target control of the CSL/NICD complex without relevant safety concerns.
To read the Press Release please click here
To see the Cellestia 2021 ASCO Poster click here
To watch the presentation at ASCO click here
Previous news
